| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 415.46% | £360,819.65 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 319.73% | £293,810.71 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 229.09% | £230,361.68 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 62.44% | £113,706.18 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 49.79% | £104,852.72 |
| Lord Mance |
|
Stryker / NYQ:SYK | 28.93% | £90,254.18 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 2.36% | £71,650.76 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -0.08% | £69,944.43 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -0.51% | £69,646.20 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -39.76% | £42,171.32 |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -55.29% | £31,299.09 | |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |